• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Accolade Inc.

    11/14/24 7:34:26 PM ET
    $ACCD
    Business Services
    Consumer Discretionary
    Get the next $ACCD alert in real time by email
    SC 13G/A 1 d884186dsc13ga.htm SC 13G/A SC 13G/A

     

     

    United States

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Accolade, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    00437E102

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 00437E102

     

    1.   

    Names of Reporting Persons

     

    Bellevue Group AG

    2.   

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☒  (b) ☐

     

    3.   

    SEC Use Only

     

    4.   

    Citizenship or Place of Organization

     

    Switzerland

    Number of

    Shares Beneficially  

    Owned by

    Each

    Reporting

    Person

    with:

       5.   

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    640,865

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    640,865

    9.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    640,865

    10.   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11.   

    Percent of Class Represented by amount in Row (9)

     

    0.8%

    12.   

    Type of Reporting Person (See Instructions)

     

    CO, HC


    CUSIP No. 00437E102

     

    1.   

    Names of Reporting Persons

     

    Bellevue Asset Management AG

    2.   

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☒  (b) ☐

     

    3.   

    SEC Use Only

     

    4.   

    Citizenship or Place of Organization

     

    Switzerland

    Number of

    Shares Beneficially  

    Owned by

    Each

    Reporting

    Person

    with:

       5.   

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    640,865

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    640,865

    9.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    640,865

    10.   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11.   

    Percent of Class Represented by amount in Row (9)

     

    0.8%

    12.   

    Type of Reporting Person (See Instructions)

     

    CO, HC, FI


    CUSIP No. 00437E102

     

    1.   

    Names of Reporting Persons

     

    Bellevue Asset Management (UK) Ltd.

    2.   

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☒  (b) ☐

     

    3.   

    SEC Use Only

     

    4.   

    Citizenship or Place of Organization

     

    England and Wales

    Number of

    Shares Beneficially  

    Owned by

    Each

    Reporting

    Person

    with:

       5.   

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    0

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    0

    9.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0

    10.   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11.   

    Percent of Class Represented by amount in Row (9)

     

    0.0%

    12.   

    Type of Reporting Person (See Instructions)

     

    FI


    Item 1.

    1(a) Name of Issuer: Accolade, Inc.

    1(b) Address of Issuer’s Principal Executive Offices:

    1201 Third Avenue, Suite 1700, Seattle, Washington 98101

    Item 2.

    2(a) Name of Person Filing: Bellevue Group AG (“Bellevue Group”) on behalf of its wholly-owned subsidiaries, Bellevue Asset Management (UK) Ltd. (“BAM UK”) and Bellevue Asset Management AG (“BAM,” and together with Bellevue Group and BAM UK, the “Reporting Persons”).

    2(b) Address of Principal Business Office or, if none, Residence:

    Bellevue Group: Seestrasse 16, Kuesnacht, Switzerland, CH-8700

    BAM:     Seestrasse 16, Kuesnacht, Switzerland, CH-8700

    BAM UK:   32 London Bridge Street, 24th Floor, London, England SE1 9SG

    2(c) Citizenship:

    Bellevue Group AG: Switzerland

    Bellevue Asset Management AG: Switzerland

    Bellevue Asset Management (UK) Ltd.: England and Wales

    2(d) Title of Class of Securities: Common Stock

    2(e) CUSIP Number: 00437E102

    Item 4. Ownership

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    This statement is filed jointly by Bellevue Group, BAM and BAM UK. BAM UK is a wholly-owned subsidiary of BAM. Each of BAM UK and BAM is a wholly-owned subsidiary of Bellevue Group.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    By signing below I also certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to investment advisers and investment companies is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.


    SIGNATURES

    After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Bellevue Group AG

     

    Date: November 14, 2024     By:   /s/ Stefano Montalbano
          Signatory Authority
        Name:   Stefano Montalbano
        Title:   Chief Financial Officer
    Date: November 14, 2024     By:   /s/ Christoph Eisenring
          Signatory Authority
        Name:   Christoph Eisenring
        Title:   Head Legal & Compliance
    Bellevue Asset Management AG      
    Date: November 14, 2024     By:   /s/ Martin Gubler
          Signatory Authority
        Name:   Martin Gubler
        Title:   Chief Financial Officer
    Date: November 14, 2024     By:   /s/ Ivo Betschart
          Signatory Authority
        Name:   Ivo Betschart
        Title:   Chief Finance & Controlling


    Bellevue Asset Management (UK) Ltd.

     

    Date: November 14, 2024     By:   /s/ Markus Peter
          Signatory Authority
        Name:   Markus Peter
        Title:   Director


    Exhibit Index

    Exhibit A: Agreement among Bellevue Group AG, Bellevue Asset Management AG and Bellevue Asset Management (UK) Ltd. with respect to the filing of this disclosure statement.*

     

    *

    Previously filed as an exhibit to Bellevue Group AG, Bellevue Asset Management AG and Bellevue Asset Management (UK) Ltd.’s Schedule 13G filed with the Securities and Exchange Commission on February 14, 2023.

     

    9

    Get the next $ACCD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACCD

    DatePrice TargetRatingAnalyst
    6/28/2024$13.00 → $8.00Buy
    Needham
    2/26/2024$16.00Outperform
    Leerink Partners
    1/17/2024$16.00 → $14.00Neutral
    DA Davidson
    1/3/2024$13.00Equal Weight
    Barclays
    5/24/2023$16.50Neutral → Buy
    BofA Securities
    4/12/2023$18.00Overweight
    Stephens
    3/23/2023$16.00Neutral → Buy
    Guggenheim
    2/9/2023$14.00Buy → Hold
    Jefferies
    More analyst ratings

    $ACCD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Transcarent Completes Merger With Accolade

    Creating the Most Comprehensive Health and Care Platform for Employers and Health Plans Serving 20 Million Members & 1,700 Employer and Health Plan Clients Today Transcarent announced the successful completion of its merger with Accolade, the leading health advocacy, expert medical opinion, and virtual primary care company in the market. The combined organization now serves over 20 million Members and more than 1,700 employer and health plan clients as the One Place for Health and Care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250407811112/en/ With the completion of the transaction, Transcarent will offer a health and car

    4/8/25 9:22:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Stockholders Approve Merger Between Accolade and Transcarent

    SEATTLE, March 27, 2025 (GLOBE NEWSWIRE) -- Accolade (NASDAQ:ACCD) announced that Accolade stockholders voted to approve the merger with Transcarent at the Accolade special meeting of stockholders (the "Special Meeting") held earlier today. The final, certified voting results for the Special Meeting will be provided in a Form 8-K filed with the U.S. Securities and Exchange Commission. The transaction remains on track to be completed in the second quarter of calendar year 2025 and is subject to customary closing conditions, including the receipt of certain state regulatory approvals. Upon completion of the transaction, Accolade will become a privately held company and shares of Accol

    3/27/25 4:05:00 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Welcomes Oshi Health to Trusted Partner Ecosystem

    Partnership increases access to specialized, whole-person clinical care for people managing digestive health conditions SEATTLE, March 6, 2025 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD) has partnered with Oshi Health, a leading virtual clinic specializing in gastrointestinal (GI) conditions that delivers convenient, accessible, whole-person care through a collaborative, multidisciplinary approach. This partnership adds to Accolade's existing GI health partnership with Cylinder and reinforces Accolade's commitment to delivering best-in-class health solutions to customers and their employee and member populations.

    3/6/25 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Singh Rajeev returned $10,429,525 worth of shares to the company (1,483,574 units at $7.03), closing all direct ownership in the company (SEC Form 4)

    4 - Accolade, Inc. (0001481646) (Issuer)

    4/8/25 10:52:21 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form 4 filed by Director Lepore Dawn G

    4 - Accolade, Inc. (0001481646) (Issuer)

    4/8/25 10:37:34 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Director Kent Cindy returned $84,093 worth of shares to the company (11,962 units at $7.03), closing all direct ownership in the company (SEC Form 4)

    4 - Accolade, Inc. (0001481646) (Issuer)

    4/8/25 10:36:43 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    SEC Filings

    View All

    $ACCD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form 15-12G filed by Accolade Inc.

    15-12G - Accolade, Inc. (0001481646) (Filer)

    4/18/25 9:10:20 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13D/A filed by Accolade Inc.

    SCHEDULE 13D/A - Accolade, Inc. (0001481646) (Subject)

    4/10/25 9:03:06 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form 25-NSE filed by Accolade Inc.

    25-NSE - Accolade, Inc. (0001481646) (Subject)

    4/8/25 3:43:21 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Needham reiterated coverage on Accolade with a new price target

    Needham reiterated coverage of Accolade with a rating of Buy and set a new price target of $8.00 from $13.00 previously

    6/28/24 7:50:50 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Leerink Partners initiated coverage on Accolade with a new price target

    Leerink Partners initiated coverage of Accolade with a rating of Outperform and set a new price target of $16.00

    2/26/24 7:00:19 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    DA Davidson resumed coverage on Accolade with a new price target

    DA Davidson resumed coverage of Accolade with a rating of Neutral and set a new price target of $14.00 from $16.00 previously

    1/17/24 7:07:47 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Financials

    Live finance-specific insights

    View All

    Transcarent To Acquire Accolade

    Combined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment Transcarent's Generative AI WayFinding and care experiences combined with Accolade's Advocacy, Expert Medical Opinion, and Primary Care will deliver on the promise of ‘One Place for Health and Care' Accolade shareholders to receive $7.03 per share in cash SAN FRANCISCO and SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, announced that they have entered into a definitive agreement under which Transcarent wil

    1/8/25 8:30:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade to Announce Fiscal Third Quarter 2025 Financial Results

    SEATTLE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal third quarter 2025 financial results on Thursday, January 9, 2024 after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here. (https://register.vevent.com/register/BI0dce2f02ed2f44c8901127623aa788c3) Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via a li

    12/16/24 8:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Announces Results for Fiscal Second Quarter 2025

    SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal second quarter ended August 31, 2024. "As we enter the second half of fiscal year 2025, we are well positioned to deliver our first full year of Adjusted EBITDA profitability and positive cash flow. Accolade is proving the scalability and profitability of a business model and strategy that is fundamentally designed to improve the lives of millions of people and their families. Our focus remains on solving the Physician Gap through a physician-led advocacy approach that engages the entire healthcare ecosystem and enables a better healthcare experience for our members," s

    10/8/24 7:00:29 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Leadership Updates

    Live Leadership Updates

    View All

    Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction

    SAN FRANCISCO and SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, today announced the expiration of the waiting period under the Hart-Scott-Rodino ("HSR") Antitrust Improvements Act of 1976 with respect to the previously announced merger between the two companies. The transaction remains on track to be completed in the second quarter of calendar year 2025, subject to Accolade stockholder approval and satisfaction of other customary closing conditions. Glen Tullman, Chief Executive Officer of Transcarent, said, "With this milestone behind us, we ar

    2/24/25 5:20:27 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Expands Physician-Executive Leadership to Enhance Care Delivery and Improve the Healthcare Experience

    Welcomes Dr. Connie Hwang as chief medical officer, creates roles of chief health officer and chief nursing officer SEATTLE, Sept. 18, 2023 /PRNewswire/ -- Accolade (NASDAQ:ACCD) announced the expansion of its care delivery team, strengthening the company's ability to streamline healthcare experiences through physician-led advocacy. Connie Hwang, MD, MPH, joins Accolade to lead population health strategies for employers and health plans. Led by Shantanu Nundy, MD, executive vice president, chief health officer, the care delivery leadership team includes Dr. Hwang, senior vice president, chief medical officer; James Wantuck, MD, senior vice president, associate chief medical officer and co-fo

    9/18/23 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade appoints new chief information security officer

    With the addition of senior vice president and CISO, Kelli Burns, Accolade further elevates its focus on trusted, personalized relationships through exceptional information security for its members and customers SEATTLE, July 25, 2022 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD), the company that provides millions of people and their families with Personalized Healthcare, announced today that Kelli Burns has joined the organization as senior vice president, chief information security officer. Burns, a former consultant with Ernst & Young LLP (EY US) focused on cybersecurity en

    7/25/22 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Accolade Inc.

    SC 13G/A - Accolade, Inc. (0001481646) (Subject)

    11/14/24 7:34:26 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Accolade Inc.

    SC 13G/A - Accolade, Inc. (0001481646) (Subject)

    11/12/24 12:26:15 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form SC 13G filed by Accolade Inc.

    SC 13G - Accolade, Inc. (0001481646) (Subject)

    11/4/24 11:51:44 AM ET
    $ACCD
    Business Services
    Consumer Discretionary